Cytokinetics (CYTK) and Amgen Inc. (AMGN) Announce COSMIC-HF Data; Roth Capital Raises Price Target to $22
Tweet Send to a Friend
Roth Capital maintained a Buy rating on Cytokinetics (NASDAQ: CYTK), and raised the price target to $22.00 (from $18.00), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
